Scientific discovery is at the core of Biogen Idec. Our dedicated scientists are inspired each day to create meaningful therapeutic advancements for patients and, this year alone, we are planning to spend approximately $1 billion on research and development to achieve that goal.
Our robust pipeline, which includes 15 products in Phase II clinical trials and beyond, underlies our commitment to delivering medicines and services to patients in need. Our core areas of focus include those where we have established expertise: neurology, oncology and immunology. We have also leveraged our capabilities to expand development into the promising new therapeutic areas of cardiovascular disease and hemophilia.
